AI-Powered Startup engaged in pre-cancer screening ‘Make it Happen in the Philippines’

  • Published on May 23, 2022
  • |

AI-Powered Startup engaged in pre-cancer screening ‘Make it Happen in the Philippines’

The Philippine Board of Investments (BOI), led by BOI Governor and Trade Undersecretary Rafaelita M. Aldaba (center) together with BOI-International Investments Promotion Service, headed by Director Lanie O. Dormiendo (third from left), met with the officers of InterVenn Biosciences on May 13, 2022. Mr. Randolph Barr (second from left), Chief Information Security Officer, and Mr. Axel Kornerup (rightmost), General Manager of InterVenn, discussed their plan to hire more than 100 software developers and engineers in the Philippines, which will form the backbone to run the company’s proprietary Artificial Intelligence (AI) technology. Their team has also expressed appreciation for BOI’s efforts in assisting InterVenn to realize its vision that “No one should ever be blindsided by disease”.

InterVenn Biosciences, a startup founded and headed by Aldo Carrascoso, a Filipino native based in South San Francisco, California, with offices in Australia and Malaysia aside from the Philippines, is pioneering a new AI-powered approach to predict, prevent, and observe disease progression. InterVenn has raised a total of US$278.1 million in funding over five rounds. InterVenn has developed a powerful AI-enabled software platform that can perform glycoproteomic analysis and can work on a variety of mass spectrometry instruments to create high-throughput, automated analysis solutions for both research and clinical applications. The platform identifies patient-specific cancer biomarkers and uses those to develop liquid biopsy tests that can detect cancer and determine how well each patient will respond to available treatments.

InterVenn is currently working on the development and commercialization of Dawn™, assessing whether a patient is likely to benefit from immuno-oncology therapies. The startup has also developed GLORI™ - a laboratory-developed test for ovarian cancer diagnosis which recently completed clinical and analytical validation based on a multinational trial, VOCAL, carried out in South East Asia, including the Philippine General Hospital, National Kidney and Transplant Institute, and The Medical City in the Philippines, in the US, and Australia. (BOI)

About the Author

Kate Shiene Austria

Information Officer III

Information Officer III under the Creative Production Services Division of the Philippine Information Agency. 

Feedback / Comment

Get in touch